P
Pictor
Biotechnology company that develops, manufactures and markets immunodiagnostic products
About Pictor
Pictor Limited specializes in multiplexed immunodiagnostic technology, focusing on high throughput antibody testing systems. The company operates in the healthcare diagnostics market, serving medical laboratories and healthcare providers. Pictor's core product is the PictArray™ SARS CoV 2 ELISA Kit, which, in collaboration with SCIENION, is used for international commercialization. This kit allows for the detection of multiple analytes in a single test, specifically IgG antibodies to both the Spike Protein and Nucleocapsid Protein of SARS CoV 2. This capability leads to better health outcomes through earlier diagnosis, prevention, and treatment of COVID-19. Pictor's business model revolves around selling these diagnostic kits and related imaging systems, generating revenue through product sales and strategic partnerships. The company aims to enhance cost-effective and efficient operations in the diagnostics field.
Source: Dealroom company dataAt a glance
- Founded
- 2006
- Headquarters
- Auckland, New Zealand
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- MBMarko Bogoievski
K1W1
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pictor on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pictor on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.